28 September 2017 - FDA grants qualified infectious disease product and fast track designation to ETX2514SUL, the combination of ETX2514 with sulbactam.

Entasis Therapeutics today announced the presentation of data on ETX2514 at IDWeek 2017, which is being held from October 4-8 in San Diego, California. ETX2514 is a novel, broad-spectrum beta-lactamase inhibitor with activity against class A, C and D beta-lactamases. 

The posters will highlight Phase 1 clinical data on ETX2514 as well as efficacy against Acinetobacter baumannii in combination with sulbactam in pre-clinical testing.

Read Entasis Therapeutics press release